title: Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis.
abstract: OBJECTIVE
  The objective of the study was to assess the effectiveness of intravesical treatment for painful bladder syndrome (PBS).
  
  
  METHODS
  A systematic review was performed until December 31, 2010. The selection criteria included only randomized controlled trials of PBS patients who received intravesical treatment. The primary outcomes measures were clinical and urodynamic parameters. Relative risk and mean differences were used for binary and continuous outcomes respectively, with confidence interval of 95%.
  
  
  RESULTS
  The search strategy identified 770; however, only 28 eligible trials met methodological requirements for complete analysis. Altogether, the review included four treatment modalities: resiniferatoxin, Bacillus Calmette-Guérin (BCG), oxybutynin, and alkalinized lidocaine. Meta-analysis of BCG therapy showed improvement in symptoms according to the Wisconsin Interstitial Cystitis Symptom Inventory, but no difference in 24-h urinary frequency.
  
  
  CONCLUSIONS
  Meta-analysis showed an improvement exclusively of the symptoms as measured by the Wisconsin Interstitial Cystitis Inventory, but not in 24-h urinary frequency, with BCG therapy. Further randomized clinical trials, including trials of more recent drugs, are required for evaluation of intravesical therapies for PBS.
authors.affiliation: Urogynecology Division, Department of Gynecology and Obstetrics, USP, Sao Paulo, Brazil. priscila.matsuoka@hotmail.com
authors.forename: P K
authors.initials: PK
authors.lastname: Matsuoka
authors.forename: J M
authors.initials: JM
authors.lastname: Haddad
authors.forename: A M
authors.initials: AM
authors.lastname: Pacetta
authors.forename: E C
authors.initials: EC
authors.lastname: Baracat
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000779:Anesthetics, Local / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D018856:Cystitis, Interstitial / Q000188:drug therapy*; D004224:Diterpenes / Q000627:therapeutic use; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009498:Neurotoxins / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000779:Anesthetics, Local; D001500:BCG Vaccine; D004224:Diterpenes; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D009498:Neurotoxins; D008012:Lidocaine; C024353:resiniferatoxin; C005419:oxybutynin